NMN

Nicotinamide Mononucleotide

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

An NAD+ precursor with a small, population-specific human study and separate animal research; broad health and longevity benefits are unestablished.

Plain English

NMN research is early. One small study measured a specific outcome in a defined group, while animal findings cannot tell us whether the same effects occur in people.

Overview

NMN is a nicotinamide adenine dinucleotide (NAD+) precursor. A small randomized study in postmenopausal women with prediabetes reported a muscle insulin-sensitivity finding in its defined population and intervention context. Preclinical NMN findings, including animal work, are not human efficacy evidence. NCT03151239 is a specific registry record and does not independently establish clinical benefit.

Research Summary

Yoshino et al. reported a prespecified muscle insulin-sensitivity outcome in a small, defined trial population of postmenopausal women with prediabetes. The study does not establish broad metabolic, cardiovascular, cognitive, safety, or longevity benefit. NCT03151239 is a registry record rather than standalone efficacy evidence.

Research Areas

  • NAD+ biosynthesis
  • NAD+ metabolism
  • Study-specific muscle insulin sensitivity
  • Preclinical aging research

Safety & Risks

Serious Risks

  • Long-term safety and clinical benefit of NMN supplementation remain unestablished.
  • Animal or mechanistic findings should not be treated as human efficacy evidence.
United States
This record does not establish a U.S. drug approval, dietary-supplement marketing status, or therapeutic indication for NMN.
United Kingdom
Not assessed in this record.
Australia
Not assessed in this record.
Canada
Not assessed in this record.